CLIP3

Summary

CLIP3 (CAP-Gly domain containing linker protein 3, HGNC:24314) is a protein-coding gene on chromosome 19q13.12, encoding CAP-Gly domain-containing linker protein 3 (Q96DZ5). Functions as a cytoplasmic linker protein.

This gene encodes a member of the cytoplasmic linker protein 170 family. Members of this protein family contain a cytoskeleton-associated protein glycine-rich domain and mediate the interaction of microtubules with cellular organelles. The encoded protein plays a role in T cell apoptosis by facilitating the association of tubulin and the lipid raft ganglioside GD3. The encoded protein also functions as a scaffold protein mediating membrane localization of phosphorylated protein kinase B. Alternatively spliced transcript variants have been observed for this gene.

Source: NCBI Gene 25999 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 77 total
• MANE Select transcript: NM_015526

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24314
Approved symbol	CLIP3
Name	CAP-Gly domain containing linker protein 3
Location	19q13.12
Locus type	gene with protein product
Status	Approved
Aliases	CLIPR-59, RSNL1
Ensembl gene	ENSG00000105270
Ensembl biotype	protein_coding
OMIM	607382
Entrez	25999

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 7 protein_coding, 2 retained_intron

ENST00000360535, ENST00000585466, ENST00000586457, ENST00000590559, ENST00000592017, ENST00000593074, ENST00000904679, ENST00000904680, ENST00000923666

RefSeq mRNA: 2 — MANE Select: NM_015526 NM_001199570, NM_015526

CCDS: CCDS12486

Canonical transcript exons

ENST00000360535 — 14 exons

Exon	Start	End
ENSE00001057348	36019171	36019306
ENSE00001057351	36018898	36019026
ENSE00001151412	36016907	36016979
ENSE00001151418	36017386	36017450
ENSE00001151425	36017655	36017778
ENSE00001151432	36017848	36017991
ENSE00001151451	36026147	36026265
ENSE00001151457	36026586	36026747
ENSE00001265900	36024396	36024632
ENSE00001430168	36014660	36016212
ENSE00002502399	36027132	36027271
ENSE00002695934	36032192	36032415
ENSE00002959485	36032724	36032873
ENSE00003789288	36026952	36027045

Expression profiles

Bgee: expression breadth ubiquitous, 231 present calls, max score 99.08.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 31.7782 / max 990.3994, expressed in 1244 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
180644	31.5654	1244
180643	0.1649	69
180642	0.0479	14

Top tissues by expression

279 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	99.08	gold quality
ganglionic eminence	UBERON:0004023	98.99	gold quality
prefrontal cortex	UBERON:0000451	98.94	gold quality
lateral nuclear group of thalamus	UBERON:0002736	98.89	gold quality
right hemisphere of cerebellum	UBERON:0014890	98.89	gold quality
substantia nigra pars reticulata	UBERON:0001966	98.87	gold quality
cerebellar hemisphere	UBERON:0002245	98.86	gold quality
cerebellar cortex	UBERON:0002129	98.82	gold quality
Brodmann (1909) area 46	UBERON:0006483	98.82	gold quality
right frontal lobe	UBERON:0002810	98.80	gold quality
substantia nigra pars compacta	UBERON:0001965	98.78	gold quality
entorhinal cortex	UBERON:0002728	98.78	gold quality
postcentral gyrus	UBERON:0002581	98.77	gold quality
cerebellum	UBERON:0002037	98.76	gold quality
parietal lobe	UBERON:0001872	98.72	gold quality
frontal cortex	UBERON:0001870	98.68	gold quality
ventricular zone	UBERON:0003053	98.66	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	98.56	gold quality
neocortex	UBERON:0001950	98.47	gold quality
lateral globus pallidus	UBERON:0002476	98.35	gold quality
temporal lobe	UBERON:0001871	98.34	gold quality
Brodmann (1909) area 9	UBERON:0013540	98.34	gold quality
cerebral cortex	UBERON:0000956	98.33	gold quality
amygdala	UBERON:0001876	98.17	gold quality
superior frontal gyrus	UBERON:0002661	98.08	gold quality
cingulate cortex	UBERON:0003027	98.08	gold quality
anterior cingulate cortex	UBERON:0009835	98.07	gold quality
superior vestibular nucleus	UBERON:0007227	98.05	gold quality
hypothalamus	UBERON:0001898	98.03	gold quality
pons	UBERON:0000988	97.98	gold quality

Single-cell (SCXA)

Detected in 6 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-GEOD-84465	yes	22.73
E-ANND-3	yes	9.10
E-GEOD-93593	yes	6.89
E-MTAB-7037	no	34.47
E-CURD-112	no	2.44
E-MTAB-9543	no	2.43

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

120 targeting CLIP3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-6740-5P	100.00	65.64	932
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-6753-3P	99.93	66.57	637
HSA-MIR-7107-3P	99.93	66.73	627
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-6857-5P	99.87	65.32	985
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-130B-5P	99.83	68.50	1888
HSA-MIR-6844	99.82	70.69	2423
HSA-MIR-7110-5P	99.80	67.84	1712
HSA-MIR-6842-5P	99.80	67.54	1587
HSA-MIR-4659A-3P	99.80	72.62	4248
HSA-MIR-4659B-3P	99.80	72.62	4248
HSA-MIR-3913-5P	99.78	67.26	968
HSA-MIR-3150A-3P	99.76	64.44	1640
HSA-MIR-6763-5P	99.76	64.68	1767
HSA-MIR-6885-3P	99.75	70.36	3187
HSA-MIR-586	99.65	70.40	2051
HSA-MIR-5700	99.64	69.88	2280
HSA-MIR-651-5P	99.64	68.49	1104
HSA-MIR-6861-3P	99.60	68.46	444
HSA-MIR-6752-5P	99.59	67.32	1243

Literature-anchored findings (GeneRIF, showing 8)

• play an important role in membrane-microtubule interactions. (PMID:11854307)
• CLIPR-59 prevents microtubule-raft interactions (PMID:15262990)
• CLIPR-59 may act as a typical chaperone, allowing a prompt interaction between tubulin and the raft component GD3 during cell apoptosis triggered by CD95/Fas (PMID:20052288)
• CLIPR-59 modulates ubiquitination of RIP1, resulting in the formation of Complex-II and thus promoting Caspase-8 activation to induce apoptosis by TNF-alpha. (PMID:22297296)
• DHHC17 is a ClipR-59 palmitoyltransferase that modulates ClipR-59 plasma membrane binding. (PMID:24001771)
• CLIPR-59 interacts with Spy1 resulting in its decreased association with a de-ubiquitinating enzyme in glioblastoma cells. (PMID:26017671)
• this study indicates that inhibition of miRNA-593-3p by insulin promotes glucose metabolism through the regulation of Slc38a1 and CLIP3 expression, and provides a new insight into the role and mechanism of insulin-induced glycolysis. (PMID:27613819)
• Downregulated CLIP3 induces radioresistance by enhancing stemness and glycolytic flux in glioblastoma. (PMID:34488821)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	clip3	ENSDARG00000054456
mus_musculus	Clip3	ENSMUSG00000013921
rattus_norvegicus	Clip3	ENSRNOG00000050104

Paralogs (4): CLIP2 (ENSG00000106665), CLIP4 (ENSG00000115295), CLIP1 (ENSG00000130779), DCTN1 (ENSG00000204843)

Protein

Protein identifiers

CAP-Gly domain-containing linker protein 3 — Q96DZ5 (reviewed: Q96DZ5)

Alternative names: Cytoplasmic linker protein 170-related 59 kDa protein

All UniProt accessions (2): Q96DZ5, K7ESF3

UniProt curated annotations — full annotation on UniProt →

Function. Functions as a cytoplasmic linker protein. Involved in TGN-endosome dynamics. May modulate the cellular compartmentalization of AKT kinase family and promote its cell membrane localization, thereby playing a role in glucose transport in adipocytes.

Subunit / interactions. Homodimer. Interacts with AKT1 and AKT2; when AKT1 and AKT2 are phosphorylated and activated, affinity is higher for AKT2. Interacts with ZDHHC13 (via ANK repeats). Interacts with ZDHHC17 (via ANK repeats).

Subcellular location. Cell membrane. Cytoplasm. Golgi apparatus. Golgi stack.

Post-translational modifications. Palmitoylation by ZDHHC17 regulates association with the plasma membrane.

Domain organisation. Microtubule association is inhibited by the ANK repeats and the Golgi localization region (GoLD).

Miscellaneous. The N-terminal half is dispensable for proper Golgi targeting, whereas the GoLD region is required.

RefSeq proteins (2): NP_001186499, NP_056341* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000938	CAP-Gly_domain	Domain
IPR002110	Ankyrin_rpt	Repeat
IPR036770	Ankyrin_rpt-contain_sf	Homologous_superfamily
IPR036859	CAP-Gly_dom_sf	Homologous_superfamily

Pfam: PF01302, PF12796

UniProt features (31 total): strand 8, compositionally biased region 4, repeat 3, region of interest 3, modified residue 2, lipid moiety-binding region 2, mutagenesis site 2, helix 2, domain 2, chain 1, sequence variant 1, turn 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
2CP0	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96DZ5-F1	74.93	0.43

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 374, 401, 534, 535

Mutagenesis-validated functional residues (2):

Position	Phenotype
509	inhibits interaction with zdhhc13 and zdhhc17.
534–535	strongly reduced plasma membrane association and decrease in the levels of akt at the plasma membrane.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-5357905	Regulation of TNFR1 signaling

MSigDB gene sets: 273 (showing top): GCACCTT_MIR18A_MIR18B, VERHAAK_AML_WITH_NPM1_MUTATED_DN, GOBP_NEGATIVE_REGULATION_OF_PROTEIN_CONTAINING_COMPLEX_ASSEMBLY, GNF2_RTN1, GCM_MAP4K4, GOBP_CARBOHYDRATE_TRANSPORT, GOBP_REGULATION_OF_PROTEIN_POLYMERIZATION, GOBP_CYTOPLASMIC_MICROTUBULE_ORGANIZATION, GOBP_POSITIVE_REGULATION_OF_ENDOCYTOSIS, YAGI_AML_WITH_INV_16_TRANSLOCATION, GOBP_REGULATION_OF_MICROTUBULE_BASED_PROCESS, TGCGCANK_UNKNOWN, GOBP_REGULATION_OF_PHOSPHORYLATION, GOBP_INTRACELLULAR_PROTEIN_TRANSPORT, GOBP_LIPOPROTEIN_METABOLIC_PROCESS

GO Biological Process (11): positive regulation of protein phosphorylation (GO:0001934), positive regulation of D-glucose transmembrane transport (GO:0010828), peptidyl-L-cysteine S-palmitoylation (GO:0018230), negative regulation of microtubule polymerization (GO:0031115), cytoplasmic microtubule organization (GO:0031122), positive regulation of apoptotic process (GO:0043065), membrane biogenesis (GO:0044091), fat cell differentiation (GO:0045444), positive regulation of endocytosis (GO:0045807), protein transport along microtubule (GO:0098840), positive regulation of protein localization to plasma membrane (GO:1903078)

GO Molecular Function (4): microtubule binding (GO:0008017), ganglioside binding (GO:0035594), microtubule plus-end binding (GO:0051010), protein binding (GO:0005515)

GO Cellular Component (14): nucleus (GO:0005634), Golgi stack (GO:0005795), trans-Golgi network (GO:0005802), cytosol (GO:0005829), plasma membrane (GO:0005886), cell cortex (GO:0005938), early endosome membrane (GO:0031901), trans-Golgi network membrane (GO:0032588), microtubule plus-end (GO:0035371), membrane raft (GO:0045121), recycling endosome membrane (GO:0055038), cytoplasm (GO:0005737), Golgi apparatus (GO:0005794), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
TNF signaling	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoplasm	3
cellular anatomical structure	3
intracellular membrane-bounded organelle	2
Golgi apparatus subcompartment	2
cell periphery	2
endosome membrane	2
regulation of protein phosphorylation	1
protein phosphorylation	1
positive regulation of protein modification process	1
positive regulation of phosphorylation	1
regulation of D-glucose transmembrane transport	1
positive regulation of transmembrane transport	1
D-glucose transmembrane transport	1
peptidyl-S-diacylglycerol-L-cysteine biosynthetic process from peptidyl-cysteine	1
protein palmitoylation	1
negative regulation of microtubule polymerization or depolymerization	1
regulation of microtubule polymerization	1
negative regulation of protein polymerization	1
microtubule polymerization	1
negative regulation of supramolecular fiber organization	1
microtubule cytoskeleton organization	1
supramolecular fiber organization	1
apoptotic process	1
regulation of apoptotic process	1
positive regulation of programmed cell death	1
cellular component biogenesis	1
cell differentiation	1
endocytosis	1
regulation of endocytosis	1
positive regulation of transport	1
positive regulation of cellular component organization	1
intracellular protein transport	1
transport along microtubule	1
microtubule-based protein transport	1
protein localization to plasma membrane	1
regulation of protein localization to plasma membrane	1
positive regulation of protein localization to cell periphery	1
positive regulation of protein localization to membrane	1
tubulin binding	1
glycosphingolipid binding	1

Protein interactions and networks

STRING

1133 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CLIP3	ANK1	P16157	518
CLIP3	ANK3	Q12955	511
CLIP3	ANK2	Q01484	510
CLIP3	ZDHHC17	Q8IUH5	505
CLIP3	TOR1A	O14656	475
CLIP3	ZDHHC13	Q8IUH4	473
CLIP3	MALRD1	Q5VYJ5	462
CLIP3	CHST8	Q9H2A9	443
CLIP3	ZBTB7C	A1YPR0	443
CLIP3	ZDHHC22	Q8N966	436
CLIP3	TTC38	Q5R3I4	432
CLIP3	PHKB	Q93100	426
CLIP3	TBC1D4	O60343	416
CLIP3	PACSIN1	Q9BY11	409
CLIP3	PIP5K1A	Q99755	407

IntAct

29 interactions, top by confidence:

A	B	Type	Score
GOLGA2	CLIP3	psi-mi:“MI:0915”(physical association)	0.560
CLIP3	CEP83	psi-mi:“MI:0915”(physical association)	0.560
TLE5	CLIP3	psi-mi:“MI:0915”(physical association)	0.560
GRN	CLIP3	psi-mi:“MI:0915”(physical association)	0.560
CLIP3	HSPB1	psi-mi:“MI:0915”(physical association)	0.560
CLIP3	WFS1	psi-mi:“MI:0915”(physical association)	0.560
CLIP3	KIF1B	psi-mi:“MI:0915”(physical association)	0.560
RNF11	CLIP3	psi-mi:“MI:0915”(physical association)	0.560
PB2		psi-mi:“MI:0914”(association)	0.350
DLK1	PLPP3	psi-mi:“MI:0914”(association)	0.350
MICB	LGALS8	psi-mi:“MI:0914”(association)	0.350
FMR1	CLIP3	psi-mi:“MI:0915”(physical association)	0.000
CLIP3	GOLGA2	psi-mi:“MI:0915”(physical association)	0.000
CEP83	CLIP3	psi-mi:“MI:0915”(physical association)	0.000
TLE5	CLIP3	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (23): AKT1 (Affinity Capture-Western), AKT2 (Affinity Capture-Western), CLIP3 (Affinity Capture-Western), CLIP3 (Affinity Capture-Western), AKT2 (Reconstituted Complex), AKT1 (Reconstituted Complex), SPDYA (Affinity Capture-Western), CLIP3 (Affinity Capture-Western), CLIP3 (Affinity Capture-Western), CYLD (Affinity Capture-Western), CLIP3 (Biochemical Activity), CLIP3 (Two-hybrid), GOLGA2 (Two-hybrid), CEP83 (Two-hybrid), CLIP3 (Affinity Capture-RNA)

ESM2 similar proteins: A0A0D1E2P6, A0A0D2XVZ5, A0A0P0VG31, A0A0P1AAU8, A0A287B8J2, A2WYG9, A4QP73, B9EHT4, B9F2Y7, D0NCC1, J9VKM5, O08788, O59739, P0C7L7, P0CP26, P0CP27, P14725, P28023, P39742, P82874, P92792, Q10MW6, Q13217, Q14203, Q149L6, Q27968, Q28I38, Q54M21, Q54NS3, Q58DR2, Q5JJI4, Q5JNB5, Q5R686, Q5R6H3, Q5ZI13, Q6PCJ1, Q6YUL8, Q7ZXQ8, Q8TBM8, Q91YW3

Diamond homologs: A0A287B8J2, B9EHT4, O08788, O42184, O42667, O55156, P28023, P30622, P33420, P35458, Q10235, Q14203, Q20728, Q54Z01, Q5E951, Q5R686, Q5U243, Q66HD5, Q6PCJ1, Q8CI96, Q8N3C7, Q922J3, Q96DZ5, Q99426, Q9D1E6, Q9JK25, Q9NQT8, Q9UDT6, Q9VJE5, Q9Z0H8, E9Q309, P13496, P34531, Q01397, Q15813, Q32KS0, Q55CN0, Q5FVQ9, Q5RBD9, Q5U378

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

77 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	64
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1524 predictions. Top by Δscore:

Variant	Effect	Δscore
19:36016210:AACCT:A	acceptor_loss	1.0000
19:36016212:CCT:C	acceptor_loss	1.0000
19:36016213:C:CG	acceptor_loss	1.0000
19:36016214:T:A	acceptor_loss	1.0000
19:36016975:CGTCA:C	acceptor_gain	1.0000
19:36016977:TCA:T	acceptor_gain	1.0000
19:36016978:CA:C	acceptor_gain	1.0000
19:36016978:CAC:C	acceptor_gain	1.0000
19:36016978:CACT:C	acceptor_loss	1.0000
19:36016979:AC:A	acceptor_loss	1.0000
19:36016980:C:CC	acceptor_gain	1.0000
19:36016980:C:CG	acceptor_loss	1.0000
19:36016981:T:C	acceptor_loss	1.0000
19:36017380:A:C	donor_gain	1.0000
19:36017381:CTCA:C	donor_gain	1.0000
19:36017382:TCA:T	donor_loss	1.0000
19:36017383:CA:C	donor_loss	1.0000
19:36017384:A:AC	donor_gain	1.0000
19:36017385:C:CT	donor_gain	1.0000
19:36017385:CT:C	donor_gain	1.0000
19:36017385:CTTG:C	donor_gain	1.0000
19:36017385:CTTGT:C	donor_gain	1.0000
19:36017386:TTGT:T	donor_gain	1.0000
19:36017387:TGTC:T	donor_gain	1.0000
19:36017446:CAATC:C	acceptor_gain	1.0000
19:36017447:AATC:A	acceptor_gain	1.0000
19:36017448:ATC:A	acceptor_gain	1.0000
19:36017448:ATCC:A	acceptor_loss	1.0000
19:36017449:TC:T	acceptor_gain	1.0000
19:36017449:TCC:T	acceptor_loss	1.0000

AlphaMissense

3542 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:36017678:G:C	F476L	1.000
19:36017678:G:T	F476L	1.000
19:36017679:A:C	F476C	1.000
19:36017679:A:G	F476S	1.000
19:36017680:A:G	F476L	1.000
19:36017682:A:T	V475D	1.000
19:36017685:C:T	G474E	1.000
19:36017686:C:A	G474W	1.000
19:36017686:C:G	G474R	1.000
19:36017686:C:T	G474R	1.000
19:36017699:G:C	C469W	1.000
19:36017700:C:T	C469Y	1.000
19:36017705:G:C	F467L	1.000
19:36017705:G:T	F467L	1.000
19:36017706:A:G	F467S	1.000
19:36017707:A:G	F467L	1.000
19:36017710:A:C	Y466D	1.000
19:36017724:A:T	V461D	1.000
19:36017728:A:G	S460P	1.000
19:36017730:C:A	G459V	1.000
19:36017730:C:T	G459D	1.000
19:36017731:C:A	G459C	1.000
19:36017731:C:G	G459R	1.000
19:36017742:C:A	G455V	1.000
19:36017742:C:T	G455D	1.000
19:36017743:C:G	G455R	1.000
19:36017757:A:G	L450P	1.000
19:36017766:C:T	G447D	1.000
19:36017767:C:G	G447R	1.000
19:36017771:C:A	W445C	1.000

dbSNP variants (sampled 300 via entrez): RS1000028536 (19:36032921 G>A,C,T), RS1000105680 (19:36029821 T>C), RS1000210396 (19:36026492 C>G,T), RS1000496667 (19:36028111 C>T), RS1000582183 (19:36029431 A>G), RS1000613564 (19:36014695 T>A), RS1000737033 (19:36014488 G>A), RS1001190810 (19:36023075 C>A), RS1001267171 (19:36025212 A>C), RS1001616869 (19:36025366 A>G), RS1001987694 (19:36029891 C>A), RS1002050116 (19:36029582 G>A), RS1002375382 (19:36016740 G>A), RS1002443314 (19:36018384 G>T), RS1002615392 (19:36024792 T>G)

Disease associations

OMIM: gene MIM:607382 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

39 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, affects expression, increases expression, increases methylation	5
trichostatin A	affects cotreatment, decreases expression	3
sodium arsenite	increases abundance, affects cotreatment, increases expression, decreases expression	3
afuresertib	increases expression	1
6,7-dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine	decreases expression	1
FR900359	increases phosphorylation	1
moringin	decreases expression	1
bisphenol A	increases expression	1
lead acetate	affects cotreatment, increases expression	1
cobaltous chloride	increases expression	1
butyraldehyde	decreases expression	1
cyfluthrin	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
jinfukang	increases expression	1
(+)-JQ1 compound	increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Temozolomide	decreases expression	1
Decitabine	affects expression	1
Acetaminophen	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Arsenic	increases abundance, increases expression	1
Aspirin	increases expression	1
Cadmium	decreases expression, increases abundance	1
Cannabidiol	decreases expression	1
Carbamazepine	affects expression	1
Cisplatin	affects expression	1
Diethylhexyl Phthalate	decreases expression	1
Chlorpyrifos	increases expression	1
Mustard Gas	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.